Nutritional lipidomics: Molecular metabolism, analytics, and diagnostics

Molecular Nutrition and Food Research

Volumn 57, Issue 8, 2013, Pages 1319-1335

  Smilowitz, Jennifer T ^a   Zivkovic, Angela M ^a   Wan, Yu Jui Yvonne ^b   Watkins, Steve M ^c   Nording, Malin L ^d   Hammock, Bruce D ^a,e   German, J Bruce ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c METABOLON INC   (United States)

^d UMEÅ UNIVERSITY   (Sweden)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bile acids; Lipids; Mass spectrometry; Nutrition; Oxylipins

Indexed keywords

LIPID; OXYLIPIN;

BILE ACIDS; CHEMISTRY; COHORT ANALYSIS; DIET; HOMEOSTASIS; HUMAN; LIPID METABOLISM; MASS SPECTROMETRY; METHODOLOGY; NUTRITION; NUTRITIONAL SCIENCE; NUTRITIONAL STATUS; PHENOTYPE; REVIEW; RISK FACTOR;

BILE ACIDS; LIPIDS; MASS SPECTROMETRY; NUTRITION; OXYLIPINS;

COHORT STUDIES; DIET; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIPIDS; NUTRITIONAL SCIENCES; NUTRITIONAL STATUS; PHENOTYPE; RISK FACTORS;

EID: 84881295598     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200808     Document Type: Review

References (164)

1. Dennis, E. A., Lipidomics joins the omics evolution. Proc. Natl. Acad. Sci. USA 2009, 106, 2089-2090.
2. Kien, C. L., Bunn, J. Y., Poynter, M. E., Stevens, R. et al., A lipidomics analysis of the relationship between dietary fatty acid composition and insulin sensitivity in young adults. Diabetes 2013, 62, 1054-1063.
3. Pietiläinen, K. H., Sysi-Aho, M., Rissanen, A., Seppänen-Laakso, T. et al., Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-a monozygotic twin study. PLoS One 2007, 2, e218.
4. Watkins, S. M., Reifsnyder, P. R., Pan, H.-J., German, J. B. et al., Lipid metabolome-wide effects of the PPAR-γ agonist rosiglitazone. J. Lipid Res. 2002, 43, 1809-1817.
5. Pike, L. J., Han, X., Gross, R. W., Epidermal growth factor receptors are localized to lipid rafts that contain a balance of inner and outer leaflet lipids: a shotgun lipidomics study. J. Biol. Chem. 2005, 280, 26796-26804.
6. Su, X., Han, X., Mancuso, D. J., Abendschein, D. R. et al., Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. Biochemistry 2005, 44, 5234-5245.
7. Jain, M., Petzold, C. J., Schelle, M. W., Leavell, M. D. et al., Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids via metabolic coupling. Proc. Natl. Acad. Sci. USA 2007, 104, 5133-5138.
8. Gronert, K., Kantarci, A., Levy, B. D., Clish, C. B. et al., A molecular defect in intracellular lipid signaling in human neutrophils in localized aggressive periodontal tissue damage. J. Immunol. 2004, 172, 1856-1861.
9. Fahy, E., Subramaniam, S., Brown, H. A., Glass, C. K. et al., A comprehensive classification system for lipids. J. Lipid Res. 2005, 46, 839-862.
10. Fahy, E., Cotter, D., Sud, M., Subramaniam, S., Lipid classification, structures and tools. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2011, 1811, 637-647.
11. Fahy, E., Subramaniam, S., Murphy, R. C., Nishijima, M. et al., Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 2009, 50, S9-S14.
12. Dennis, E. A., Deems, R. A., Harkewicz, R., Quehenberger, O. et al., A mouse macrophage lipidome. J. Biol. Chem. 2010, 285, 39976-39985.
13. Quehenberger, O., Dennis, E. A., The human plasma lipidome. N. Engl. J. Med. 2011, 365, 1812-1823.
14. van Meer, G., Leeflang, B. R., Liebisch, G., Schmitz, G. et al., The European lipidomics initiative: enabling technologies. Meth. Enzymol. 2007, 432, 213-232.
15. Wenk, M. R., The emerging field of lipidomics. Nat. Rev. Drug Discov. 2005, 4, 594-610.
16. Wheelock, C. E., Wheelock, Å. M., Kawashima, S., Diez, D. et al., Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol. BioSyst. 2009, 5, 588-602.
17. Han, X., Gross, R. W., Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 2004, 24, 367-412.
18. Han, X., Yang, K., Gross, R. W., Multi-dimensional mass spectrometry-based shotgun lipidomics and novel strategies for lipidomic analyses. Mass Spectrom. Rev. 2011, 31, 134-178.
19. Hellmuth, C., Weber, M., Koletzko, B., Peissner, W., Nonesterified fatty acid determination for functional lipidomics: comprehensive ultrahigh performance liquid chromatography-tandem mass spectrometry quantitation, qualification, and parameter prediction. Anal. Chem. 2012, 84, 1483-1490.
20. Masoodi, M., Nicolaou, A., Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20, 3023-3029.
21. Takatera, A., Takeuchi, A., Saiki, K., Morisawa, T. et al., Quantification of lysophosphatidylcholines and phosphatidylcholines using liquid chromatography-tandem mass spectrometry in neonatal serum. J. Chromatogr. B 2006, 838, 31-36.
22. Kathiresan, S., Manning, A., Demissie, S., D'Agostino, R. et al., A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med. Genet. 2007, 8, S8-S17.
23. Wolk, A., Furuheim, M., Vessby, B., Fatty acid composition of adipose tissue and serum lipids are valid biological markers of dairy fat intake in men. J. Nutr. 2001, 131, 828-833.
24. Fuhrman, B., Lavy, A., Aviram, M., Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am. J. Clin. Nutr. 1995, 61, 549-554.
25. Rzehak, P., Heinrich, J., Klopp, N., Schaeffer, L. et al., Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes. Br. J. Nutr. 2009, 101, 20-26.
26. Xie, L., Innis, S. M., Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J. Nutr. 2008, 138, 2222-2228.
27. Lemaitre, R. N., Tanaka, T., Tang, W., Manichaikul, A. et al., Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet. 2011, 7, e1002193.
28. Cao, H., Gerhold, K., Mayers, J., Wiest, M. et al., Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 2008, 134, 933-944.
29. Raatz, S. K., Young, L. R., Picklo, M. J., Sauter, E. R. et al., Total dietary fat and fatty acid content modifies plasma phospholipid fatty acids, desaturase activity indices, and urinary prostaglandin E in women. Nutr. Res. 2012, 32, 1-7.
30. Elizondo, A., Araya, J., Rodrigo, R., Poniachik, J. et al., Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity 2007, 15, 24-31.
31. Chorell, E., Svensson, M. B., Moritz, T., Antti, H., Physical fitness level is reflected by alterations in the human plasma metabolome. Mol. BioSyst. 2012, 8, 1187-1196.
32. Thomas, B., Ghebremeskel, K., Lowy, C., Offley-Shore, B. et al., Plasma fatty acids of neonates born to mothers with and without gestational diabetes. Prostag., Leukotr. Essent, Fatty Acids 2005, 72, 335-341.
33. Watkins, S. M., Lin, T. Y., Davis, R. M., Ching, J. R. et al., Unique phospholipid metabolism in mouse heart in response to dietary docosahexaenoic or alpha-linolenic acids. Lipids 2001, 36, 247-254.
34. Ottestad, I., Hassani, S., Borge, G. I., Kohler, A. et al., Fish oil supplementation alters the plasma lipidomic profile and increases long-chain PUFAs of phospholipids and triglycerides in healthy subjects. PLoS One 2012, 7, e42550.
35. Smilowitz, J., Wiest, M., Watkins, S., Teegarden, D. et al., Lipid metabolism predicts changes in body composition during energy restriction in overweight humans. J. Nutr. 2009, 139, 222-229.
36. Lecerf, J. M., Fatty acids and cardiovascular disease. Nutr. Rev. 2009, 67, 273-283.
37. Erkkila, A., de Mello, V. D., Riserus, U., Laaksonen, D. E., Dietary fatty acids and cardiovascular disease: an epidemiological approach. Prog. Lipid Res. 2008, 47, 172-187.
38. Smilowitz, J. T., Wiest, M. M., Teegarden, D., Zemel, M. B. et al., Dietary fat and not calcium supplementation or dairy product consumption is associated with changes in anthropometrics during a randomized, placebo-controlled energy-restriction trial. Nutr. Metab. 2011, 8, 67-77.
39. Yang, J., Dong, H., Hammock, B. D., Profiling the regulatory lipids: another systemic way to unveil the biological mystery. Curr. Opin. Lipidol. 2011, 22, 197-203.
40. Yang, J., Schmelzer, K., Georgi, K., Hammock, B. D., Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal. Chem. 2009, 81, 8085-8093.
41. Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K. et al., International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58, 726-741.
42. Wang, Y. X., PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res. 2010, 20, 124-137.
43. Berger, J., Moller, D. E., The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53, 409-435.
44. Braissant, O., Wahli, W., Differential expression of peroxisome proliferator-activated receptor-α, -β, and-γ during rat embryonic development. Endocrinology 1998, 139, 2748-2754.
45. Lemay, D. G., Hwang, D. H., Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J. Lipid Res. 2006, 47, 1583-1587.
46. Yu, S., Rao, S., Reddy, J. K., Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr. Mol. Med. 2003, 3, 561-572.
47. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S. et al., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA 1994, 91, 7355-7359.
48. Lee, S. S., Pineau, T., Drago, J., Lee, E. J. et al., Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell Biol. 1995, 15, 3012-3022.
49. Michalik, L., Desvergne, B., Wahli, W., Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat. Rev. Cancer 2004, 4, 61-70.
50. Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J. et al., Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 1999, 103, 1489-1498.
51. Leone, T. C., Weinheimer, C. J., Kelly, D. P., A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA 1999, 96, 7473-7478.
52. Lu, Y., Boekschoten, M. V., Wopereis, S., Müller, M. et al., Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice. Physiol. Genomics 2011, 43, 1307-1318.
53. Oster, R. T. O. R., Tishinsky, J. M. T. J., Yuan, Z. Y. Z., Robinson, L. E. R. L., Docosahexaenoic acid increases cellular adiponectin mRNA and secreted adiponectin protein, as well as PPAR-γ mRNA, in 3T3-L1 adipocytes. Appl. Physiol. Nutr. Metab. 2010, 35, 783-789.
54. Sethi, S., Ziouzenkova, O., Ni, H., Wagner, D. D. et al., Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR-α. Blood 2002, 100, 1340-1346.
55. Houten, S. M., Watanabe, M., Auwerx, J., Endocrine functions of bile acids. EMBO J. 2006, 25, 1419-1425.
56. Watanabe, M., Houten, S. M., Wang, L., Moschetta, A. et al., Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 2004, 113, 1408-1418.
57. Stayrook, K. R., Bramlett, K. S., Savkur, R. S., Ficorilli, J. et al., Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005, 146, 984-991.
58. Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A. et al., Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439, 484-489.
59. Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A. et al., A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 2000, 6, 517-526.
60. Pircher, P. C., Kitto, J. L., Petrowski, M. L., Tangirala, R. K. et al., Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 2003, 278, 27703-27711.
61. Neimark, E., Chen, F., Li, X., Shneider, B. L., Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 2004, 40, 149-156.
62. Barbier, O., Torra, I. P., Sirvent, A., Claudel, T. et al., FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003, 124, 1926-1940.
63. Thomas, A. M., Hart, S. N., Kong, B., Fang, J. et al., Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 2010, 51, 1410-1419.
64. Chiang, J. Y., Bile acids: regulation of synthesis. J. Lipid Res. 2009, 50, 1955-1966.
65. Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A. et al., A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 2000, 6, 517-526.
66. Kuipers, F., Claudel, T., Sturm, E., Staels, B., The Farnesoid X receptor (FXR) as modulator of bile acid metabolism. Rev. Endocr. Metab. Disord. 2004, 5, 319-326.
67. Stedman, C., Robertson, G., Coulter, S., Liddle, C., Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J. Biol. Chem. 2004, 279, 11336-11343.
68. Gnerre, C., Blattler, S., Kaufmann, M. R., Looser, R. et al., Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 2004, 14, 635-645.
69. Pircher, P. C., Kitto, J. L., Petrowski, M. L., Tangirala, R. K. et al., Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 2003, 278, 27703-27711.
70. Bergheim, I., Harsch, S., Mueller, O., Schimmel, S. et al., Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J. Lipid Res. 2006, 47, 42-50.
71. Landrier, J. F., Eloranta, J. J., Vavricka, S. R., Kullak-Ublick, G. A., The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G476-G485.
72. Cariou, B., The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab. 2008, 34, 685-691.
73. Gyamfi, M. A., He, L., French, S. W., Damjanov, I. et al., Hepatocyte retinoid X receptor alpha-dependent regulation of lipid homeostasis and inflammatory cytokine expression contributes to alcohol-induced liver injury. J. Pharmacol. Exp. Ther. 2008, 324, 443-453.
74. Yang, F., Huang, X., Yi, T., Yen, Y. et al., Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67, 863-867.
75. Bishop-Bailey, D., Walsh, D. T., Warner, T. D., Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. USA 2004, 101, 3668-3673.
76. Kawamata, Y., Fujii, R., Hosoya, M., Harada, M. et al., AG protein-coupled receptor responsive to bile acids. J. Biol. Chem. 2003, 278, 9435-9440.
77. Forman, B. M., Goode, E., Chen, J., Oro, A. E. et al., Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81, 687-693.
78. Zhao, X., Peter, A., Fritsche, J., Elcnerova, M. et al., Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am. J. Physiol. Endocrinol. Metab. 2009, 296, E384-E393.
79. Patti, M. E., Houten, S. M., Bianco, A. C., Bernier, R. et al., Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity 2012, 17, 1671-1677.
80. Eckel-Mahan, K. L., Patel, V. R., Mohney, R. P., Vignola, K. S. et al., Coordination of the transcriptome and metabolome by the circadian clock. Proc. Natl. Acad. Sci. USA 2012, 109, 5541-5546.
81. Yeagle, P. L., Modulation of membrane function by cholesterol. Biochimie 1991, 73, 1303-1310.
82. Roda, A., Festi, D., Sama, C., Mazzella, G. et al., Enzymatic determination of cholesterol in bile. Clin. Chim. Acta 1975, 64, 337-341.
83. Miller, W. L., Molecular biology of steroid hormone synthesis. Endocr. Rev. 1988, 9, 295-318.
84. Field, F. J., Born, E., Mathur, S. N., Stanol esters decrease plasma cholesterol independently of intestinal ABC sterol transporters and Niemann-Pick C1-like 1 protein gene expression. J. Lipid Res. 2004, 45, 2252-2259.
85. Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L. H. et al., Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 1999, 22, 336-345.
86. Tall, A. R., Costet, P., Wang, N., Regulation and mechanisms of macrophage cholesterol efflux. J. Clin. Invest. 2002, 110, 899-904.
87. Yvan-Charvet, L., Ranalletta, M., Wang, N., Han, S. et al., Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 2007, 117, 3900-3908.
88. Calkin, A. C., Tontonoz, P., Liver X receptor signaling pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1513-1518.
89. Makishima, M., Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J. Pharmacol. Sci. 2005, 97, 177-183.
90. Lo Sasso, G., Murzilli, S., Salvatore, L., D'Errico, I. et al., Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metabol. 2010, 12, 187-193.
91. Costet, P., Luo, Y., Wang, N., Tall, A. R., Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 2000, 275, 28240-28245.
92. Hozoji, M., Munehira, Y., Ikeda, Y., Makishima, M. et al., Direct interaction of nuclear liver X receptor-beta with ABCA1 modulates cholesterol efflux. J. Biol. Chem. 2008, 283, 30057-30063.
93. Repa, J. J., Turley, S. D., Lobaccaro, J. A., Medina, J. et al., Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289, 1524-1529.
94. McNeish, J., Aiello, R. J., Guyot, D., Turi, T. et al., High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. USA 2000, 97, 4245-4250.
95. Murthy, S., Born, E., Mathur, S. N., Field, F. J., LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. J. Lipid Res. 2002, 43, 1054-1064.
96. Krishnan, S., Newman, J. W., Hembrooke, T. A., Keim, N. L., Variation in metabolic responses to meal challenges differing in glycemic index in healthy women: is it meaningful? Nutr. Metab. (Lond.) 2012, 9, 26-36.
97. Armstrong, P., Kelley, D. S., Newman, J. W., Staggers, F. E., Sr. et al., Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans. J. Nutr. 2012, 142, 1417-1428.
98. Shearer, G. C., Harris, W. S., Pedersen, T. L., Newman, J. W., Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res. 2010, 51, 2074-2081.
99. Zivkovic, A. M., Yang, J., Georgi, K., Hegedus, C. et al., Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alternations. Metabolomics 2012, 8, 1102-1113.
100. Bakker, G., van Erk, M., Pellis, L., Wopereis, S. et al., An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach. Am. J. Clin. Nutr. 2010, 91, 1044-1059.
101. Zivkovic, A., German, J., Metabolomics for assessment of nutritional status. Curr. Op. Clin. Nut. Metab. Care 2009, 12, 501-507.
102. Bernini, P., Bertini, I., Luchinat, C., Nepi, S. et al., Individual human phenotypes in metabolic space and time. J. Proteome Res. 2009, 8, 4264-4271.
103. Holmes, E., Wilson, I., Nicholson, J., Metabolic phenotyping in health and disease. Cell 2008, 134, 714-717.
104. Vinaixa, M., Rodri guez, M., Rull, A., Beltra N., R. et al., Metabolomic Assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. J. Proteome Res. 2010, 9, 2527-2538.
105. Winnike, J., Li, Z., Wright, F., Macdonald, J. et al., Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin. Pharmacol. Ther. 2010, 88, 45-51.
106. Yap, I. K. S., Angley, M., Veselkov, K. A., Holmes, E. et al., Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J. Proteome Res. 2010, 9, 2996-3004.
107. Cao, H., Gerhold, K., Mayers, J. R., Wiest, M. M. et al., Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 2008, 134, 933-944.
108. Grapov, D., Adams, S. H., Pedersen, T. L., Garvey, W. T. et al., Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One 2012, 7, e48852.
109. Zhou, X., Mao, J., Ai, J., Deng, Y. et al., Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS One 2012, 7, e48889.
110. Burdge, G. C., Calder, P. C., Plasma cytokine response during the postprandial period: a potential causal process in vascular disease? Br. J. Nutr. 2005, 93, 3-9.
111. Bell, D. S., O'Keefe, J. H., Jellinger, P., Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr. Pract. 2008, 14, 112-124.
112. Bansal, S., Buring, J. E., Rifai, N., Mora, S. et al., Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298, 309-316.
113. Jackson, K. G., Poppitt, S. D., Minihane, A. M., Postprandial lipemia and cardiovascular disease risk: interrelationships between dietary, physiological and genetic determinants. Atherosclerosis 2012, 220, 22-33.
114. Karpe, F., Mechanisms of postprandial hyperlipidaemia-remnants and coronary artery disease. Diabet. Med. 1997, 14(Suppl 3), S60-S66.
115. Proctor, S. D., Mamo, J. C. L., Intimal retention of cholesterol derived from apolipoprotein B100-and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1595-1600.
116. Tall, A., Plasma cholesteryl ester transfer protein. J. Lipid Res. 1993, 34, 1255-1274.
117. Guerin, M., Egger, P., Soudant, C., Le Goff, W. et al., Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J. Lipid Res. 2002, 43, 1652-1660.
118. Rashid, S., Barrett, P. H. R., Uffelman, K. D., Watanabe, T. et al., Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscl. Thromb. Vasc. Biol. 2002, 22, 483-487.
119. Lamarche, B., Uffelman, K. D., Carpentier, A., Cohn, J. S. et al., Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo AI in healthy men. J. Clin. Invest. 1999, 103, 1191-1194.
120. van der Steeg, W. A., Holme, I., Boekholdt, S. M., Larsen, M. L. et al., High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein AI: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 2008, 51, 634-642.
121. Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D. et al., High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79, 8-15.
122. Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H. et al., Cholesteryl ester transfer protein a novel target for raising HDL and inhibiting atherosclerosis. Arterioscl. Thromb. Vasc. Biol. 2003, 23, 160-167.
123. Galeano, N. F., Al-Haideri, M., Keyserman, F., Rumsey, S. C. et al., Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J. Lipid Res. 1998, 39, 1263-1273.
124. Chapman, M., Guerin, M., Bruckert, E., Atherogenic, dense low-density lipoproteins: pathophysiology and new therapeutic approaches. Eur. Heart J. 1998, 19, A24-A30.
125. Carmena, R., Duriez, P., Fruchart, J. C., Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004, 109, III2-III7.
126. Maggi, F. M., Raselli, S., Grigore, L., Redaelli, L. et al., Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J. Clin. Endocrinol. Metab. 2004, 89, 2946-2950.
127. Zivkovic, A., Wiest, M., Nguyen, U., Nording, M. et al., Assessing individual metabolic responsiveness to a lipid challenge using a targeted metabolomic approach. Metabolomics 2009, 5, 209-218.
128. Carroll, J. F., Kaiser, K. A., Franks, S. F., Deere, C. et al., Influence of BMI and gender on postprandial hormone responses. Obesity 2007, 15, 2974-2983.
129. Mittendorfer, B., Sexual dimorphism in human lipid metabolism. J. Nutr. 2005, 135, 681-686.
130. Romon, M., Lebel, P., Fruchart, J. C., Dallongeville, J., Postprandial leptin response to carbohydrate and fat meals in obese women. J. Am. Coll. Nutr. 2003, 22, 247-251.
131. Gill, J. M., Malkova, D., Hardman, A. E., Reproducibility of an oral fat tolerance test is influenced by phase of menstrual cycle. Horm. Metab. Res. 2005, 37, 336-341.
132. Nappo, F., Esposito, K., Cioffi, M., Giugliano, G. et al., Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J. Am. Coll. Cardiol. 2002, 39, 1145-1150.
133. Lin, P. Y., Nhung, B. T., Khan, N. C., Sarukura, N. et al., Effect of Vietnamese common diet on postprandial blood glucose level in adult females. J. Nutr. Sci. Vitaminol. (Tokyo) 2007, 53, 247-252.
134. van Oostrom, A. J., Real, J. T., Carmena, R., Ascaso, J. F. et al., Daylong triglyceridaemia in healthy Mediterranean and northern European subjects. Neth. J. Med. 2004, 62, 279-285.
135. Ordovas, J. M., Corella, D., Cupples, L. A., Demissie, S. et al., Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. Am. J. Clin. Nutr. 2002, 75, 38-46.
136. Neufeld, E. B., Stonik, J. A., Demosky, S. J., Jr., Knapper, C. L. et al., The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J. Biol. Chem. 2004, 279, 15571-15578.
137. Cohn, J. S., McNamara, J. R., Cohn, S. D., Ordovas, J. M. et al., Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J. Lipid Res. 1988, 29, 925-936.
138. Trygg, J., Holmes, E., Lundstedt, T., Chemometrics in metabonomics. J. Proteome Res. 2006, 6, 469-479.
139. Niemelä, P. S., Castillo, S., Sysi-Aho, M., Orešič, M., Bioinformatics and computational methods for lipidomics. J. Chromatogr. B 2009, 877, 2855-2862.
140. Chorell, E., Moritz, T., Branth, S., Antti, H. et al., Predictive metabolomics evaluation of nutrition-modulated metabolic stress responses in human blood serum during the early recovery phase of strenuous physical exercise. J. Proteome Res. 2009, 8, 2966-2977.
141. Lundstedt, T., Seifert, E., Abramo, L., Thelin, B. et al., Experimental design and optimization. Chemometr. Intell. Lab. Syst. 1998, 42, 3-40.
142. Antti, H., Ebbels, T. M. D., Keun, H. C., Bollard, M. E. et al., Statistical experimental design and partial least squares regression analysis of biofluid metabonomic NMR and clinical chemistry data for screening of adverse drug effects. Chemometr. Intell. Lab. Syst. 2004, 73, 139-149.
143. de Aguiar, P. F., Bourguignon, B., Khots, M. S., Massart, D. L. et al., D-optimal designs. Chemometr. Intell. Lab. Syst. 1995, 30, 199-210.
144. Wold, S., Esbensen, K., Geladi, P., Principal component analysis. Chemometr. Intell. Lab. Syst. 1987, 2, 37-52.
145. Carlson, R., Lundstedt, T., Scope of organic synthetic reactions. Multivariate methods for exploring the reaction space. An example with the Willgerodt-Kindler reaction. Acta Chem. Scand. 1987, B41, 164-173.
146. Trygg, J., Wold, S., Orthogonal projections to latent structures (O-PLS). J. Chemometr. 2002, 16, 119-128.
147. Madsen, R., Lundstedt, T., Trygg, J., Chemometrics in metabolomics-a review in human disease diagnosis. Anal. Chim. Acta 2010, 659, 23-33.
148. Wheelock, C. E., Wheelock, A. M., Kawashima, S., Diez, D. et al., Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol. BioSyst. 2009, 5, 588-602.
149. Kirwan, G. M., Johansson, E., Kleemann, R., Verheij, E. R. et al., Building multivariate systems biology models. Anal. Chem. 2012, 84, 7064-7071.
150. Szymańska, E., van Dorsten, F., Troost, J., Paliukhovich, I. et al., A lipidomic analysis approach to evaluate the response to cholesterol-lowering food intake. Metabolomics 2012, 8, 894-906.
151. Castro-Perez, J. M., Kamphorst, J., DeGroot, J., Lafeber, F. et al., Comprehensive LC-MSE lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J. Proteome Res. 2010, 9, 2377-2389.
152. Green, J. H., Bladeren, P. J., German, J. B., Translating nutrition innovation into practice. Food Technol. 2006, 60, 26-33.
153. Pene, F., Courtine, E., Cariou, A., Mira, J.-P., Toward theragnostics. Crit. Care Med. 2009, 37, S50-S58.
154. Picard, F. J., Bergeron, M. G., Rapid molecular theranostics in infectious diseases. Drug Discov.Today 2002, 7, 1092-1101.
155. Layre, E., Moody, D. B., Lipidomic profiling of model organisms and the world's major pathogens. Biochimie 2012, 95, 109-115.
156. Norris, P. C., Dennis, E. A., Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proc. Natl. Acad. Sci. USA 2012, 109, 8517-8522.
157. Shi, X., Yao, D., Gosnell, B. A., Chen, C., Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity. J. Lipid Res. 2012, 53, 2318-2330.
158. Ji, J., Kline, A. E., Amoscato, A., Samhan-Arias, A. K. et al., Lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of brain injury. Nat. Neurosci. 2012, 15, 1407-1413.
159. Fernando, H., Bhopale, K. K., Kondraganti, S., Kaphalia, B. S. et al., Lipidomic changes in rat liver after long-term exposure to ethanol. Toxicol. Appl. Pharmacol. 2011, 255, 127-137.
160. Angelini, R., Vitale, R., Patil, V. A., Cocco, T. et al., Lipidomics of intact mitochondria by MALDI-TOF/MS. J. Lipid Res. 2012, 53, 1417-1425.
161. Ono, A., Relationships between plasma membrane microdomains and HIV-1 assembly. Biol. Cell 2010, 102, 335-350.
162. Lagarde, M., Bernoud-Hubac, N., Guichardant, M., Expanding the horizons of lipidomics. Towards fluxolipidomics. Mol. Membr. Biol. 2012, 29, 222-228.
163. Suzuki, K. G. N., Kasai, R. S., Hirosawa, K. M., Nemoto, Y. L. et al., Transient GPI-anchored protein homodimers are units for raft organization and function. Nat. Chem. Biol. 2012, 8, 774-783.
164. Brown, M. S., Goldstein, J. L., Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J. Lipid Res. 2009, 50, S15-S27.